24/7 Market News Snapshot 19 December, 2024 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

December 19, 2024

DENVER, Colo., 19 December, 2024 (247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
Imunon, Inc. (NASDAQ:IMNN) is experiencing a notable surge in trading activity amid significant advancements in its clinical development program. Opening at $0.838, the company’s stock has risen approximately 30.89% to reach $1.087, fueled by a substantial trading volume of 1.86 million shares. This uptick reflects a growing investor interest as technical indicators point to a bullish trend, signaling renewed confidence in Imunon’s potential within the biotechnology sector.

At the forefront of Imunon’s progress is its immunotherapy treatment, IMNN-001, which has garnered positive feedback from a recent Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA). This dialogue has established alignment on critical production strategies necessary for the upcoming Phase 3 pivotal trial, scheduled to commence in the first quarter of 2025. This collaboration represents a vital step in enhancing treatment options for patients suffering from newly diagnosed advanced ovarian cancer, a demographic that often faces high recurrence rates.

Dr. Stacy Lindborg, President and CEO of Imunon, expressed optimism regarding the FDA’s support, highlighting the company’s dedication to advancing innovative therapies through compliant and effective production practices. The FDA’s approval of the potency assay for IMNN-001 is a crucial milestone, vital for both clinical research and future commercial applications. Notably, the agency has endorsed the company’s strategy to maintain consistency between internally produced product batches and those manufactured externally, reinforcing a pathway towards regulatory approval.

Leveraging its proprietary TheraPlas® platform technology, IMNN-001 aims to deliver interleukin-12 effectively, contributing to robust anticancer immune responses. As the company prepares for its pivotal Phase 3 trial, its efforts exemplify a commitment to harnessing the body’s natural defenses to offer potent therapeutic options for patients confronting significant health challenges.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.